Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia

Not Recruiting

Trial ID: NCT04789408


The goal of this clinical study is to learn more about the safety and dosing of the study drug, KITE-222, in participants with relapsed/refractory (r/r) acute myeloid leukemia (AML).

Official Title

A Phase 1 Open-label, Multicenter Study Evaluating the Safety of KITE-222, an Autologous Anti-CLL-1 CAR T-cell Therapy, in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Stanford Investigator(s)

Lori Muffly
Lori Muffly

Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)


Key Inclusion Criteria:

   - Relapse/refractory (r/r) de novo or secondary acute myeloid leukemia (AML)

   - Morphological disease in the bone marrow and/or peripheral blood within 28 days before

   - Prior exposure to the relevant agent class for individuals with AML characterized by a
   mutation targeted by an approved therapy

   - Institutional criteria for allo-SCT fitness must be met: individuals must have an
   identified stem-cell donor readily available for potential allo-SCT after therapy with

   - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

   - Adequate hematologic status, defined as:

      - Absolute neutrophil count (ANC) ≥ 1000/µL unless, in the opinion of the
      investigator, cytopenia is due to underlying leukemia

      - Platelet count ≥ 50,000/µL unless, in the opinion of the investigator,
      thrombocytopenia is due to underlying leukemia

      - Absolute lymphocyte count (ALC) ≥ 100/µL

   - Adequate renal, hepatic, pulmonary and cardiac function defined as:

      - Creatinine clearance (as estimated by the Cockcroft Gault formula) ≥ 60 mL/min

      - Serum alanine aminotransferase/aspartate aminotransferase ≤ 2.5 x upper limit of

      - Total bilirubin ≤ 1.5 mg/dL, except in individuals with Gilbert's syndrome

      - Cardiac ejection fraction ≥ 50%, no clinically significant pericardial effusion
      as determined by an echocardiogram (ECHO), and no clinically significant
      electrocardiogram (ECG) findings

      - Baseline oxygen saturation > 92% on room air and no clinically significant
      pleural effusion as determined by chest imaging

   - Contraception: males and females of childbearing potential must agree to use an
   effective method of contraception

   - Pregnancy testing: females of childbearing potential must have a negative serum or
   urine pregnancy test

Key Exclusion Criteria:

   - Diagnosis of acute promyelocytic leukemia

   - Auto-SCT within the 6 weeks before enrollment

   - Donor Lymphocyte Infusions (DLI) within 28 days prior to enrollment

   - Any drug used for graft-versus-host-disease (GVHD) within 4 weeks prior to enrollment

   - Acute GVHD grade II-IV by Mount Sinai Acute GVHD International Consortium criteria

   - Active central nervous system (CNS) disease involvement

   - Requirement for urgent therapy due to ongoing or impending oncologic emergency (eg,
   leukostasis or tumor lysis syndrome (TLS)) or the possible requirement for urgent
   therapy due to ongoing or impending oncologic emergency (eg, spinal cord compression,
   bowel obstruction, leukostasis, or TLS) at the time of enrollment or KITE-222 infusion

   - History of C-type lectin-like molecule-1 (CLL-1)-directed therapy or genetically
   modified T-cell therapy

   - History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (eg,
   cervix, bladder, or breast) unless disease free for at least 3 years after the last
   definitive therapy

   - History of severe hypersensitivity reaction to aminoglycosides

   - History of concomitant genetic syndrome associated with bone marrow failure

   - Individuals with a genetic syndrome that increases the risk of allo-SCT, including
   Down syndrome (trisomy 21)

   - History of myocardial infarction, cardiac angioplasty or stenting, unstable angina,
   New York Heart Association Class II or greater congestive heart failure, atrial
   fibrillation, or other clinically significant cardiac disease within 12 months before

   - Individuals with cardiac atrial or ventricular leukemia involvement

   - History of symptomatic deep vein thrombosis (DVT) or a pulmonary embolism within 6
   months of enrollment. History of upper extremity line related DVT within the 3 months
   of conditioning chemotherapy.

   - Primary immunodeficiency disorders

   - History of a human immunodeficiency virus (HIV) infection or acute or chronic active
   hepatitis B or C infection

   - History of an autoimmune disease resulting in end-organ injury or requiring systemic
   immunosuppression or systemic disease modifying agents within the last 2 years

   - History or presence of a CNS disorder

   - Presence or suspicion of a fungal, bacterial, viral, or other infection that is
   uncontrolled or requiring antimicrobials for management

   - Live vaccine received within the ≤ 4 weeks before enrollment, or anticipation of the
   need for a live vaccination during the course of the study

   - Inability to tolerate prophylactic antifungal and antibacterial therapy

   - Presence of any indwelling line or drain

   - Ongoing Grade 2 or higher toxicities from previous therapies, excluding hematologic

   - Females of childbearing potential who are pregnant or breastfeeding

Note: Other protocol defined Inclusion/Exclusion criteria may apply.


drug: Cyclophosphamide

drug: Fludarabine

biological: KITE-222

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Janet McDowell

New Trial Alerts